Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466340 | 1.00 | GAA (0.40) | GAAMAPTPOLBGPR142ALDH1A1 | |
| SCHEMBL1643961 | 1.00 | GAA (0.40) | GAAMAPTPOLBGPR142ALDH1A1 | |
| Imidazole SCHEMBL11208968 | 0.91 | GPR142 (0.38) | GAAMAPTPOLBGPR142ALDH1A1 | |
| Imidazole SCHEMBL27561511 | 0.91 | GPR142 (0.38) | GAAMAPTPOLBGPR142ALDH1A1 | |
| Imidazole SCHEMBL9152956 | 0.91 | GPR142 (0.38) | GAAMAPTPOLBGPR142ALDH1A1 | |
| Imidazole SCHEMBL27609343 | 0.90 | GPR142 (0.38) | GAAMAPTPOLBGPR142ALDH1A1 | |
| SCHEMBL6384640 | 0.90 | MC5R (0.39) | GPR142 | |
| SCHEMBL6447871 | 0.87 | SIRT2 (0.48) | MAPTALDH1A1 | |
| SCHEMBL2059178 | 0.87 | SIRT2 (0.48) | MAPTALDH1A1 | |
| SCHEMBL147911 | 0.87 | CPB2 (0.38) | GPR142ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| CN-115209912-A | Peptide compositions and methods of use thereof | 杜兰教育基金管理者 | 2022-10-18 | — | — | CN | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| EP-3149029-B1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-06-19 | — | — | EP | claimed |
| EP-3197874-B1 | PROCESS FOR SYNTHESIZING ERGOTHIONEINE AND RELATED COMPOUNDS | UNIV CAPE TOWN (ZA) | 2019-04-24 | — | — | EP | claimed |
| EP-3094643-B1 | LIPIDATED PEPTIDES FOR LOWERING BLOOD GLUCOSE | FYZIOLOGICKY USTAV AKADEMIE VED CESKE REPUBLIKY V V I (CZ) | 2018-10-17 | — | — | EP | claimed |
| EP-3149029-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2017-04-05 | — | — | EP | claimed |
| US-20170051031-A1 | LIPIDATED PEPTIDES AS NEUROPROTECTIVE AGENTS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2017-02-23 | — | — | US | claimed |
| JP-2002512625-A | — | — | 2002-04-23 | — | — | JP | claimed |
| WO-2002012307-A1 | UROCORTIN PROTEINS AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4960881-A | REACTING AMINO ACID WITH ALPHA-CHLORINATED CARBONATE IN SOLVENT IN PRESENCE OF ACID SCAVENGER | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-10-02 | — | — | US | claimed |
| EP-0156280-B1 | PROCESS FOR THE PREPARATION OF PEPTIDE INTERMEDIATES POOR IN RACEMATES, BELONGING TO GONADORELIN AND GONADORELIN ANALOGUES, THEIR SYNTHESIS AND INTERMEDIATES OBTAINED BY THIS PROCESS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-07 | — | — | EP | claimed |
| US-4691008-A | COUPLING A URETHANE-BLOCKED TRIPEPTIDE AND A PEPTIDE WITH A FREE AMINE USING A CONDENSATION AGENT | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | claimed |
| EP-0156280-A2 | Process for the preparation of peptide intermediates poor in racemates, belonging to gonadorelin and gonadorelin analogues, their synthesis and intermediates obtained by this process | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | GAA 3644/4885MAPT 4465/4885POLB 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.